PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we investigated the influence of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective ligands (PD-1 ligand 1 [PD-L1], PD-L2, CD80, and CD86) on MDSCs. We demonstrate that MDSCs at the tumor site show a differential expression of PD-L1 as compared with MDSCs from peripheral lymphoid organ (spleen). Hypoxia caused a rapid, dramatic, and selective up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice. This was not limited to MDSCs, as hypoxia also significantly increased the expression of PD-L1 on macrophages, dendritic cells, and tumor cells. Furthermore, PD-L1 up-regulation under hypoxia was dependent on hypoxia-inducible factor-1α (HIF-1α) but not HIF-2α. Chromatin immunoprecipitation and luciferase reporter assay revealed direct binding of HIF-1α to a transcriptionally active hypoxia-response element (HRE) in the PD-L1 proximal promoter. Blockade of PD-L1 under hypoxia enhanced MDSC-mediated T cell activation and was accompanied by the down-regulation of MDSCs IL-6 and IL-10. Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs. Simultaneous blockade of PD-L1 along with inhibition of HIF-1α may thus represent a novel approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Blockade of PD-L1 under hypoxia down-regulates MDSC IL-6 and IL-10 and enhances T cell proliferation and function. MDSCs isolated from spleens of B16-F10 tumor-bearing mice were pretreated for 30 min on ice with 5 µg/ml control antibody (IgG) or antibody against PD-L1 (PDL1 Block) and co-cultured with splenocytes under normoxia and hypoxia for 72 h. (A and B) Effect of MDSC on proliferation of splenocytes stimulated with (A) anti-CD3/CD28 coated beads or (B) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured in triplicates by [3H]thymidine incorporation and expressed as counts per minute (CPM). (C and D) MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (C) CD3+CD8+ IFN-γ+ and (D) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (**, P < 0.005; ***, P < 0.0005). Three separate experiments (in triplicates) with the same results were performed. Error bars indicate SD. (E) SYBR-GREEN RT-qPCR was performed to evaluate the mRNA expression levels of Ldha, Car-9, Arg-1, Nos2, Ncf-1, and Cybb-1. (F) Arginase enzymatic activity measured in MDSCs under indicated conditions. (G) After 72 h of MDSC co-culture with splenocytes, supernatants were collected and assayed for nitrites. Data represents three independent experiments with SD. (H) SYBR Green RT-qPCR was performed for expression levels of IL6, IL10, Il12p70, and Tgfb1 under the indicated conditions. IL-6, IL-10, IL-12p70, and TGF-β1 cytokine production and secretion was detected by (I and J) intracellular FACS staining (isotype control is gray-shaded histogram) and (K) ELISA, respectively. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). The experiment was performed in triplicates and repeated three times with the same results. Error bars indicate SD. (L–O) MDSCs isolated from spleens of B16-F10 tumor-bearing mice were co-cultured with splenocytes under normoxia and hypoxia for 72 h in the presence of either 10 µg/ml control antibody (IgG), anti–mouse IL-6 Functional Grade Purified neutralizing antibody (IL-6 Block) or anti–mouse IL-10 Functional Grade Purified neutralizing antibody (IL-10 Block). Effect of MDSCs on proliferation of splenocytes stimulated with (L) anti-CD3/CD28–coated beads or (M) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured as indicated above. MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (N) CD3+CD8+ IFN-γ+ and (O) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](https://figures.cochat.ai/paper-figures/2ba8a156b22c410c8802e99a6f19ff08/pd-l1-is-a-novel-direct-target-of-hif-1-and-its-blockade-under-hypoxia-enhanced-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to regulating components of the innate immune response, the HIFs have been linked to modulation of the adaptive immune response through upregulation of both co-inhibitory (eg. PD-L1 and CTLA4) and co-stimulatory receptors (eg. 4–1BB, OX40) on activated T cells [80, 81].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
From Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A large body of preclinical and clinical data indicates that antibody blockade of immune checkpoints can significantly enhance antitumor immunity (Pardoll, 2012; West et al., 2013).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are a heterogeneous group of relatively immature myeloid cells and several studies have described mechanisms of MDSCmediated immune suppression (Gabrilovich et al., 2012).”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“PD-1, a cell surface glycoprotein with a structure similar to cytotoxic T lymphocyte antigen 4 (CTLA-4), belongs to the B7 family of co-stimulatory/co-inhibitory molecules and plays a key part in immune regulation (Greenwald et al., 2005).”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 3×
“It is important to underline that our results are in complete agreement with previous findings by Youn et al. (2008), indicating that normoxic blockade of PD-L1 did not eliminate suppressive activity of MDSCs.”
BackgroundMethodResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 12×
“2 I) and DCs (CD11c+; Fig.”
BackgroundResultInfluentialPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · cited 6×
“As shown previously by Corzo et al. (2010), we observed higher levels of Arg-1 gene expression (Fig.”
BackgroundInfluentialOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993 · cited 1×
“2014 Vol. 211 No. 5 781-790 www.jem.org/cgi/doi/10.1084/jem.20131916 781 Brief Definit ive Report Hypoxia is a common feature of solid tumors (Semenza, 2011).”
BackgroundInfluential
Cited by
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
“Recently, Noman et al. showed that MDSCs and TAMs in hypoxic tumor regions upregulate the expression of PD-L1 as a consequence of HIF-1a signaling (Noman et al., 2014).”
BackgroundTumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationT cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
“Myeloid-derived suppressor cells (MDSCs) can directly promote immune tolerance [58].”
BackgroundThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837
Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
“In addition, hypoxia can directly upregulate, via HIF1a activation, the expression of the immune checkpoint protein PD-L1 bymyeloid-derived suppressor cells, dendritic cells, and cancer cells to aid immune suppression and evasion (Noman et al., 2014).”
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
“Under hypoxia, the expression of PD-L1 has been shown to be elevated in T lymphocytes, DCs, MDSCs, and macrophages, as well as in prostate cancer cells, breast cancer cells, and colorectal cancer cells [127, 128].”
BackgroundLactate metabolism in human health and disease
Li, X., Yang, Y., Zhang, B., Lin, X., Fu, X., An, Y., Zou, Y., Wang, J.-X., Wang, Z., & Yu, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01151-3 · Cited by 1,454
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Neutrophil diversity and plasticity in tumour progression and therapy
Jaillon, S., Ponzetta, A., Di Mitri, D., Santoni, A., Bonecchi, R., & Mantovani, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0281-y · Cited by 1,285
Metabolic Instruction of Immunity
Buck, M. D., Sowell, R. T., Kaech, S. M., & Pearce, E. L. (2017) · Cell · doi:10.1016/j.cell.2017.04.004 · Cited by 1,214
“In addition to signals received from TIL IFN-γ (Noman et al., 2014), HIF-1α also induces the expression of the suppressive ligand PD-L1 in tumor cells, TAMs, and myeloid-derived suppressor cells (MDSCs), and this can lead to TIL suppression via PD-1 (Figure 1).”
InfluentialHIF transcription factors, inflammation, and immunity
Palazon, A., Goldrath, A. W., Nizet, V., & Johnson, R. S. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.008 · Cited by 1,195
“Myeloid-derived suppressor cells are another stromal component that can dampen antitumor immunity, and HIF-1a can modulate their function and differentiation into tumor-associated macrophages (Corzo et al., 2010) and their expression of the immune checkpoint ligand PD-L1 (Noman et al., 2014).”
BackgroundMyeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
“A recent report demonstrated that HIF-1α bound to the promoter of programmed cell death ligand-1 (PD-L1) and upregulated its expression on myeloid cells (65).”
BackgroundThe hypoxic tumour microenvironment
Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G., & Amelio, I. (2018) · Oncogenesis · doi:10.1038/s41389-017-0011-9 · Cited by 1,019
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
Hou, J., Zhao, R., Xia, W., Chang, C.-W., You, Y., Hsu, J.-M., Nie, L., Chen, Y., Wang, Y.-C., Liu, C., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0575-z · Cited by 962
“The N-terminal domain (1-365) of GSDMC is sufficient to induce pyroptosis (a) 3-D structural modeling of GSDMC.”
BackgroundHypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
“(177) demonstrated in vivo that hypoxia in the TME plays a significant role in upregulation of PDL-1 on MDSCs and on their subsequent suppression of TILs.”
BackgroundImmunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J., & Umansky, V. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 839
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820
The role of HIF in immunity and inflammation
McGettrick, A. F., & O’Neill, L. A. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.002 · Cited by 768
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen, J., Jiang, C. C., Jin, L., & Zhang, X. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv615 · Cited by 767
“Increased HIF-1 levels are associated with increased PD-L1 expression and cause down-regulation of T-Cell function[66-71], suggesting hypoxic environments, which leads to increased expression of HIF-1, can also result in immune suppression in addition to promoting cell proliferation and blocking apoptosis.”
BackgroundMetabolic Reprogramming of Immune Cells in Cancer Progression
Biswas, S. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.001 · Cited by 721
“Interestingly, HIF1a can also contribute to immunosuppression through tumor-derived lactic acid, induction of PD-L1 expression on MDSCs, MDSC differentiation, and expansion of Treg cells (Ben-Shoshan et al., 2008; Colegio et al., 2014; Corzo et al., 2010; Noman et al., 2014).”
BackgroundVaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T., & Melief, C. J. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.16 · Cited by 709
Immunity, inflammation, and cancer: an eternal fight between good and evil
Shalapour, S., & Karin, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80007 · Cited by 698
“TAMs can also express programmed death-1 ligand (PD- L1) upon activation of HIF-1α in hypoxic tumor regions, further inhibiting CTL activation (70).”
InfluentialEmami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., Nedaeinia, R., Haghjooy Javanmard, S., Taherian, M., Ahmadlou, M., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01719-5 · Cited by 693
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“In addition, hypoxia-induced HIF-1α drives expression of the immune checkpoint protein PD-L1, which contributes to immune suppression and evasion (Noman et al., 2014).”
BackgroundImproving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
“PD-L1 is considered to be a target of HIF1-a, and the elevation in its expression may be a consequence of anti-angiogenic treatment-induced hypoxia [192].”
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Schaaf, M. B., Garg, A. D., & Agostinis, P. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0061-0 · Cited by 629
Clinical blockade of PD1 and LAG3 — potential mechanisms of action
Nguyen, L. T., & Ohashi, P. S. (2015) · Nature Reviews Immunology · doi:10.1038/nri3790 · Cited by 627
TAMeless traitors: macrophages in cancer progression and metastasis
Aras, S., & Zaidi, M. R. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.356 · Cited by 609
“TAMs found in hypoxic regions of the tumour upregulate PD-L1 expression via HIF-1a signalling and consequently induce T-cell suppression (Doedens et al, 2010; Noman et al, 2014).”
BackgroundSynergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
The importance of exosomal PDL1 in tumour immune evasion
Daassi, D., Mahoney, K. M., & Freeman, G. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0264-y · Cited by 598
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Huber, V., Camisaschi, C., Berzi, A., Ferro, S., Lugini, L., Triulzi, T., Tuccitto, A., Tagliabue, E., Castelli, C., & Rivoltini, L. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.03.001 · Cited by 595
HIF‐1 at the crossroads of hypoxia, inflammation, and cancer
Balamurugan, K. (2016) · International Journal of Cancer · doi:10.1002/ijc.29519 · Cited by 572
“In addition, HIF1 regulates immune checkpoint receptors by directly activating the expression of their ligands such as programmed death ligand 1 (PD-L1), which contributes to myeloid-derived suppressor cells (MDSC)-mediated T cell activation.(23) Additionally, HIF-1 exacerbates experimental colitis through the regulat…”
BackgroundImmunological landscape and immunotherapy of hepatocellular carcinoma
Prieto, J., Melero, I., & Sangro, B. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.173 · Cited by 566
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
Self-citationMyeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
“org June 2018 | Volume 9 | Article 1310 (46, 47) that interacts with PD-1 on T cells and causes their exhaustion (48).”
BackgroundRegulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
“Besides, HIF-1α regulated PD-L1 expression in LUAD and myeloid-derived suppressor cells (MDSCs) [79, 80].”
BackgroundRoles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
Rodríguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C., & Demaria, S. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.06.001 · Cited by 497
Targeting Macrophages in Cancer: From Bench to Bedside
Poh, A. R., & Ernst, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00049 · Cited by 501
Metabolism of tissue macrophages in homeostasis and pathology
Wculek, S. K., Dunphy, G., Heras-Murillo, I., Mastrangelo, A., & Sancho, D. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00791-9 · Cited by 501
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 489
“86), although information on their role in MDSC function is limited.”
Yamaguchi, H., Hsu, J.-M., Yang, W.-H., & Hung, M.-C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 493
Therapeutic targeting of the hypoxic tumour microenvironment
Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 484
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Wu, Q., You, L., Nepovimova, E., Heger, Z., Wu, W., Kuca, K., & Adam, V. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01292-6 · Cited by 485
Myeloid-Derived Suppressor Cells
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.002 · Cited by 482
“Solid tumors contain oxidatively stressed hypoxic regions, and cells within these regions contain activated hypoxia-inducible factor-1 alpha (HIF-1α).”
BackgroundInfluentialPeltanova, B., Raudenska, M., & Masarik, M. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0983-5 · Cited by 469
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 458
“Hypoxia selectively increase the expression of PD-L1, an extremely important target in ICIs, in MDSCs via HIF-1α directly binding to the PD-L1 proximal promoter [121].”
BackgroundReversing T-cell Dysfunction and Exhaustion in Cancer
Zarour, H. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1849 · Cited by 462
Wan, W., Ao, X., Chen, Q., Yu, Y., Ao, L., Xing, W., Guo, W., Wu, X., Pu, C., Hu, X., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01447-y · Cited by 457
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451
“For example, it has also been recently shown that cancer cells, cancerassociated stromal cells, and a hypoxic tumor microenvironment can up-regulate immune regulatory proteins—immune checkpoint inhibitors such as programmed death ligand-1 (PD-L1) or its receptor PD-1—that facilitate tumor escape from immune surveillan…”
BackgroundRole of tumor microenvironment in cancer progression and therapeutic strategy
Wang, Q., Shao, X., Zhang, Y., Zhu, M., Wang, F. X. C., Mu, J., Li, J., Yao, H., & Chen, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5698 · Cited by 442
Immunometabolism: Cellular Metabolism Turns Immune Regulator
Loftus, R. M., & Finlay, D. K. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.693903 · Cited by 449
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28358 · Cited by 445
“…with PD‐L1 expression enhancement and cause T‐cell function downregulation, these suggest that hypoxic environments, which cause high expression of HIF‐1, can also have a consequence in immune suppression as well as stimulating cell proliferation and blocking apoptosis (Noman et al., 2014).”
BackgroundThe immunology of renal cell carcinoma
Díaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 442
Sagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500712112 · Cited by 444
“Other studies have reported that anti–PD-L1 treatment alone is insufficient to alter MDSC arginase activity, expression of Nos-2 or NO production (25).”
Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy
Williams, C. B., Yeh, E. S., & Soloff, A. C. (2016) · npj Breast Cancer · doi:10.1038/npjbcancer.2015.25 · Cited by 444
“In conjunction, macrophages in hypoxic tumor regions promote the dysfunction of tumor-specific T cells through the HIF-1αmediated expression of inhibitory receptors of T-cell checkpoint regulation.(99) Signaling via the programmed cell death 1 (PD-1) receptor upregulated on activated T cells by the TAM-expressed ligan…”
BackgroundTargeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 443
“After the uptake of EV derived from a Lewis lung carcinoma (LLC) and glioma, MDSC displayed an increased expression of immunosuppressive molecules like arginase-1 (ARG1) and programmed death ligand 1 (PD-L1) (26).”
BackgroundInfluentialThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
“of the major echanisms of MDSC immunosuppressive function [16].”
BackgroundThe ever-expanding role of HIF in tumour and stromal biology
LaGory, E. L., & Giaccia, A. J. (2016) · Nature Cell Biology · doi:10.1038/ncb3330 · Cited by 430
Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors
Lengyel, E., Makowski, L., DiGiovanni, J., & Kolonin, M. G. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.03.004 · Cited by 424
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Wu, Q., Jiang, L., Li, S.-C., He, Q.-J., Yang, B., & Cao, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0366-x · Cited by 414
New insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
“Interestingly, both TGFb1 and CD274 (encoding for PD-L1) genes can be induced under hypoxic conditions, either directly via hypoxia-induced factors (HIFs) or indirectly through related factors (Barsoum et al., 2014; Hasmim et al., 2013; Noman et al., 2014).”
BackgroundShigeta, K., Datta, M., Hato, T., Kitahara, S., Chen, I. X., Matsui, A., Kikuchi, H., Mamessier, E., Aoki, S., Ramjiawan, R. R., et al. (2020) · Hepatology · doi:10.1002/hep.30889 · Cited by 409
“PD-L1 expression on immune, endothelial, and cancer cells is largely viewed as a marker of immune suppression, which could be induced by microenvironmental factors (for example, hypoxia or interferon gamma [IFN-γ).(9-11) PD-1 and PD-L1 expression correlate with CTL infiltration in HCC, and these parameters are associa…”
BackgroundNoman, M. Z., Hasmim, M., Messai, Y., Terry, S., Kieda, C., Janji, B., & Chouaib, S. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00207.2015 · Cited by 400
“In these sites, MDSCs induce T cell anergy, restrain the effector phase of the CD8 T cell, and can promote antigen-specific Treg cell proliferation (34, 106).”
BackgroundInfluentialSelf-citationChun, E., Lavoie, S., Michaud, M., Gallini, C. A., Kim, J., Soucy, G., Odze, R., Glickman, J. N., & Garrett, W. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.024 · Cited by 402
“MDSCs in some tumor sites show differential expression of PD-L1, and blockade of PD-L1 under hypoxic conditions abrogated MDSC-mediated suppression of T cells by modulating MDSC cytokine production (Noman et al., 2014).”
BackgroundLin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Hypoxia and the Tumor Microenvironment
Li, Y., Zhao, L., & Li, X.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036304 · Cited by 394
Regulation of PD-L1 Expression by NF-κB in Cancer
Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Di Rosa, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584626 · Cited by 385
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
Radiation-Induced Lung Injury (RILI)
Giuranno, L., Ient, J., De Ruysscher, D., & Vooijs, M. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00877 · Cited by 372
Single-cell spatial landscapes of the lung tumour immune microenvironment
Sorin, M., Rezanejad, M., Karimi, E., Fiset, B., Desharnais, L., Perus, L. J. M., Milette, S., Yu, M. W., Maritan, S. M., Doré, S., et al. (2023) · Nature · doi:10.1038/s41586-022-05672-3 · Cited by 367
Korbecki, J., Grochans, S., Gutowska, I., Barczak, K., & Baranowska-Bosiacka, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207619 · Cited by 373
Loeuillard, E., Yang, J., Buckarma, E., Wang, J., Liu, Y., Conboy, C., Pavelko, K. D., Li, Y., O’Brien, D., Wang, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137110 · Cited by 369
“T cells and G-MDSCs (ratio 4:1) (51) were cocultured in a 96-well plate with round bottom for 48h with CD3/CD28 beads (Gibco Dynabead).”
MethodHypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
Chouaib, S., Noman, M. Z., Kosmatopoulos, K., & Curran, M. A. (2017) · Oncogene · doi:10.1038/onc.2016.225 · Cited by 365
Self-citationTumor-Associated Macrophages: Implications in Cancer Immunotherapy
Petty, A. J., & Yang, Y. (2017) · Immunotherapy · doi:10.2217/imt-2016-0135 · Cited by 363
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer
Li, C., Xu, X., Wei, S., Jiang, P., Xue, L., & Wang, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001341 · Cited by 360
Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition
Taki, M., Abiko, K., Ukita, M., Murakami, R., Yamanoi, K., Yamaguchi, K., Hamanishi, J., Baba, T., Matsumura, N., & Mandai, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4459 · Cited by 351
“MDSCs also express PD-L1 on their surface,which leads toT-cell exhaustion (44).”
BackgroundMetabolic communication in the tumour–immune microenvironment
Kao, K.-C., Vilbois, S., Tsai, C.-H., & Ho, P.-C. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01002-x · Cited by 349
Liu, Z., Ravindranathan, R., Kalinski, P., Guo, Z. S., & Bartlett, D. L. (2017) · Nature Communications · doi:10.1038/ncomms14754 · Cited by 350
Gambardella, V., Castillo, J., Tarazona, N., Gimeno-Valiente, F., Martínez-Ciarpaglini, C., Cabeza-Segura, M., Roselló, S., Roda, D., Huerta, M., Cervantes, A., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102015 · Cited by 335
PD-1 and its ligands are important immune checkpoints in cancer
Dong, Y., Sun, Q., & Zhang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 334
“Binding of HIF-1α to a transcriptionally active hypoxiaresponse elements (HREs), HRE-4 and HRE-1, at two different HRE sites in the PD-L1 proximal promoter in hypoxic MSC-1 cells is comparable with their binding to an established HRE in VEGF, lactate dehydrogenase A (LDHA), and Glut1 genes [77].”
BackgroundWebb, J. R., Milne, K., Kroeger, D. R., & Nelson, B. H. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.03.008 · Cited by 335
Qian, Y., Qiao, S., Dai, Y., Xu, G., Dai, B., Lu, L., Yu, X., Luo, Q., & Zhang, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b05465 · Cited by 333
Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression
Ohl, K., & Tenbrock, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02499 · Cited by 330
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
Lim, A. R., Rathmell, W. K., & Rathmell, J. C. (2020) · eLife · doi:10.7554/elife.55185 · Cited by 327
“For example, HIF1a is known to upregulate PD-L1 on myeloid-derived suppressor cells (MDSCs), which leads to T cell exhaustion, and can promote the generation of regulatory T cells (Shen et al., 2019; Noman et al., 2014; Ben-Shoshan et al., 2008).”
BackgroundThe Role of Macrophages in Cancer Development and Therapy
Cendrowicz, E., Sas, Z., Bremer, E., & Rygiel, T. P. (2021) · Cancers · doi:10.3390/cancers13081946 · Cited by 332
“PD-L1 expression has been observed on macrophages and dendritic cells in many cancer types [47] as well as on macrophages and myeloid-derived suppressor cells isolated from the hypoxic tumor regions [48].”
BackgroundHypoxia‐inducible factors in regulation of immune responses in tumour microenvironment
Kumar, V., & Gabrilovich, D. I. (2014) · Immunology · doi:10.1111/imm.12380 · Cited by 329
Metadata
- Authors
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Istituto Oncologico Veneto (IT)
- Centre de Recherche Public de la Santé (LU)
- Institut Gustave Roussy (FR)
- University of Verona (IT)
- Unité Institut National de la Santé et de la Recherche Médicale U753, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-04-28
- Volume
- 211
- Issue
- 5
- Pages
- 781-790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4010891
- OpenAlex
- W2149360266
- Semantic Scholar
- dad078dcb463c50f1571acb3306b01954a153c29
- Cited by
- 2,166
- References
- 24
- Citations by year
- 2026: 171 · 2025: 187 · 2024: 208 · 2023: 219 · 2022: 239 · 2021: 331 · 2020: 224 · 2019: 147 · 2018: 139 · 2017: 120 · 2016: 101 · 2015: 61 · 2014: 18
- FWCI
- 48.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, HIF-1α, hypoxia, myeloid-derived suppressor cells, tumor microenvironment, immune checkpoint blockade, T cell activation, hypoxia response element, IL-10, interleukin-6, tumor-associated macrophages, cancer immunotherapy, CTLA-4, PD-1 ligands
- MeSH terms
- Animals, Diamines, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Expression Regulation, Luciferases, Lymphocyte Activation, Mice, Inbred C57BL, Organic Chemicals, Quinolines, T-Lymphocytes, Cell Hypoxia, Myeloid Cells, RNA Interference, Chromatin Immunoprecipitation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Benzothiazoles, Tumor Microenvironment, Real-Time Polymerase Chain Reaction, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.